The estimated Net Worth of Paul Thomas is at least 15.5 百万$ dollars as of 1 September 2024. Mr. Thomas owns over 11,904 units of Abiomed stock worth over 12,212,453$ and over the last 13 years he sold ABMD stock worth over 3,039,041$. In addition, he makes 269,996$ as Independent Director at Abiomed.
Sign up
Mr. Thomas ABMD stock SEC Form 4 insiders trading
Paul has made over 11 trades of the Abiomed stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 11,904 units of ABMD stock worth 4,535,662$ on 1 September 2024.
The largest trade he's ever made was exercising 11,904 units of Abiomed stock on 1 September 2024 worth over 4,535,662$. On average, Paul trades about 1,688 units every 83 days since 2011. As of 1 September 2024 he still owns at least 32,052 units of Abiomed stock.
You can see the complete history of Mr. Thomas stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Paul Thomas biography
Paul G. Thomas serves as Independent Director of the Company. Mr. Thomas co-founded Prominex, Inc., a start-up company focused on the development of molecular diagnostic assays for point-of-care infectious disease testing. Mr. Thomas currently serves as Prominex’s Chief Executive Officer. Prior to his employment with Prominex, Mr. Thomas served as the founder, President, Chief Executive Officer and director of Roka Bioscience, Inc. from September 2009 until his retirement in January 2017. Previously, he served as President, Chief Executive Officer and Chairman of LifeCell from October 1998 until its acquisition by Kinetic Concepts. Prior to joining LifeCell, Mr. Thomas held various senior positions, including President of the Pharmaceuticals division, during a 15-year tenure with Ohmeda Inc. Mr. Thomas received his Bachelor of Science in Chemistry from St. Michael’s College and his Master of Business Administration from Columbia University, and completed his postgraduate studies in chemistry at the University of Georgia.
What is the salary of Paul Thomas?
As the Independent Director of Abiomed, the total compensation of Paul Thomas at Abiomed is 269,996$. There are 11 executives at Abiomed getting paid more, with Michael Minogue having the highest compensation of 16,612,800$.
How old is Paul Thomas?
Paul Thomas is 64, he's been the Independent Director of Abiomed since 2011. There are 5 older and 12 younger executives at Abiomed. The oldest executive at Abiomed Inc. is Jeannine Rivet, 72, who is the Independent Director.
What's Paul Thomas's mailing address?
Paul's mailing address filed with the SEC is C/O AXOGEN, INC. 13631 PROGRESS BLVD, SUITE 400, ALACHUA, FL, 32615.
Insiders trading at Abiomed
Over the last 21 years, insiders at Abiomed have traded over 148,507,587$ worth of Abiomed stock and bought 232,354 units worth 4,276,073$ . The most active insiders traders include Michael R Minogue、Eric A Md Rose、David M Weber. On average, Abiomed executives and independent directors trade stock every 16 days with the average trade being worth of 5,341,900$. The most recent stock trade was executed by Martin P Sutter on 17 February 2022, trading 4,000 units of ABMD stock currently worth 1,258,840$.
What does Abiomed do?
Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.
What does Abiomed's logo look like?
Complete history of Mr. Thomas stock trades at Abiomed、Axogen、RTI Surgical
Abiomed executives and stock owners
Abiomed executives and other stock owners filed with the SEC include:
-
Michael Minogue,
Chairman of the Board, President, Chief Executive Officer -
Todd Trapp,
Chief Financial Officer, Vice President -
Andrew Greenfield,
Vice President, Chief Commercial Officer -
David Weber,
Chief Operating Officer, Senior Vice President -
Michael R. Minogue,
Chairman, CEO & Pres -
Michael Howley,
Vice President and General Manager, Global Sales -
Todd A. Trapp,
CFO & VP -
Dr. David M. Weber,
Sr. VP & COO -
Marc A. Began,
VP, Gen. Counsel & Sec. -
Andrew J. Greenfield,
VP & Chief Commercial Officer -
Dorothy Puhy,
Lead Independent Director -
Paul Thomas,
Independent Director -
Martin Sutter,
Independent Director -
Jeannine Rivet,
Independent Director -
Christopher Van Gorder,
Independent Director -
Eric Rose,
Independent Director -
Marc Began,
Vice President, General Counsel, Secretary -
Karen Mahoney,
Head of Global HR -
Michael G. Howley,
VP & GM of Global Sales -
Sarah Karr,
Communications Mang. -
Ingrid Goldberg Ward,
Director of Investor Relations -
Dr. Thorsten Siess Ph.D.,
VP & CTO -
Henri A Termeer,
Director -
Gorder Chris Van,
Director -
William J Bolt,
SVP, DA and QA -
Michael John Tomsicek,
Vice President, CFO -
W Gerald Austen,
Director -
Myron L Rolle,
Director -
Louis E Lataif,
Director -
Robert Bowen,
Chief Financial Officer -
Ronald W Dollens,
Director -
Daniel J Sutherby,
CFO -
Inc Abiomed,
Director -
Connell Desmond Jr O,
Director -
Paul Fireman,
Director -
Javier Jimenez,
VP Operations -
Anthony W Bailey,
VP, Business Development -
David M Lederman,
Chairman, CEO & President -
Charles B Haaser,
Principal Financial Officer -
Eugene D Rabe,
SVP, Global Sales & Services -
Christopher D Macdonald,
SVP Global Sales -
Sheila Marie Flaherty,
VP, General Counsel -
Robert T V Kung,
SVP, Chief Scientific Officer -
Edward E Berger,
VP, Strat. Plan & Ext. Comm. -
Patricia A. Fitch,
Vice President of Sales -
Raymond J Kelley,
VP Marketing -
David Gottlieb,
Director -
John F Obrien,
Director -
Gary Stickel,
VP of HR -
Karim Benali,
VP Product Development -
Robert Farra,
VP Engineering & Manufacturing -
Stephen C Mc Evoy,
VP and General Counsel -
Paula A Johnson,
Director